A doubly fluorescent HIV-1 reporter shows that the majority of integrated HIV-1 is latent shortly after infection

Journal of Virology

Volumn 87, Issue 8, 2013, Pages 4716-4727

  Dahabieh, Matthew S ^a   Ooms, Marcel ^b   Simon, Viviana ^b   Sadowski, Ivan ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RED GREEN HUMAN IMMUNODEFICIENCY VIRUS 1 VECTOR; UNCLASSIFIED DRUG; VIRUS VECTOR;

ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LATENT VIRUS INFECTION; LEUKEMIA CELL LINE; LONG TERMINAL REPEAT; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROVIRUS; SENSITIVITY ANALYSIS; VIRUS DETECTION; VIRUS INFECTIVITY; VIRUS LATENCY; VIRUS REACTIVATION;

GENES, REPORTER; HIV-1; HUMANS; JURKAT CELLS; STAINING AND LABELING; T-LYMPHOCYTES; VIROLOGY; VIRUS LATENCY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84875769711     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03478-12     Document Type: Article

References (54)

1. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. 1998. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 95:8869-8873.
2. +T cells can produce HIV Gag without spreading infection in a model of HIV latency. PLoS Pathog. 8:e1002818. doi:10.1371/journal.ppat.1002818.
3. Wolschendorf F, Bosque A, Shishido T, Duverger A, Jones J, Planelles V, Kutsch O. 2012. Kinase control prevents HIV-1 reactivation in spite of high levels of induced NF-κB activity. J. Virol. 86:4548-4558.
4. +T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5:512-517.
5. Richman DDD, Margolis DMM, Delaney M, Greene WCC, Hazuda D, Pomerantz RJJ. 2009. The challenge of finding a cure for HIV infection. Science 323:1304. doi:10.1126/science.1165706.
6. + T cells. Nat. Med. 9:727-728.
7. +cell HIV-1 infection without accelerating the decay of latent infection. Proc. Natl. Acad. Sci. U. S. A. 109:9523-9528.
8. Chun TW, Justement JS, Moir S, Hallahan CW, Maenza J, Mullins JI, Collier AC, Corey L, Fauci AS. 2007. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J. Infect. Dis. 195:1762-1764.
9. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, Fauci AS. 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 94:13193-13197.
10. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291-1295.
11. Choudhary S, Margolis DM. 2011. Curing HIV: pharmacologic approachesto target HIV-1 latency. Annu. Rev. Pharmacol. Toxicol. 51:397-418.
12. Ho DD, Zhang L. 2000. HIV-1 rebound after anti-retroviral therapy. Nat. Med. 6:736-737.
13. + T cells. AIDS 22:1131-1135.
14. Sagot-Lerolle N, Lamine A, Chaix ML, Boufassa F, Aboulker JP, Costagliola D, Goujard C, Pallier C, Delfraissy JF, Lambotte O. 2008. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS 22:1125-1129.
15. Siliciano JD, Lai J, Callender M, Pitt E, Zhang H, Margolick JB, Gallant JE, Cofrancesco J, Moore RD, Gange SJ, Siliciano RF. 2007. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J. Infect. Dis. 195:833-836.
16. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM. 2012. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487:482-485.
17. Colin L, Van Lint C. 2009. Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology 6:111. doi:10.1186/1742-4690-6-111.
18. Hakre S, Chavez L, Shirakawa K, Verdin E. 2012. HIV latency: experimental systems and molecular models. FEMS Microbiol. Rev. 36:706-716.
19. Pace MJ, Agosto L, Graf EH, O'Doherty U. 2011. HIV reservoirs and latency models. Virology 411:344-354.
20. Duverger A, Jones J, May J, Bibollet-Ruche F, Wagner FA, Cron RQ, Kutsch O. 2009. Determinants of the establishment of human immunodeficiency virus type 1 latency. J. Virol. 83:3078-3093.
21. Hübner W, Chen P, Del Portillo A, Liu Y, Gordon RE, Chen BK. 2007. Sequence of human immunodeficiency virus type 1 (HIV-1) Gag localization and oligomerization monitored with live confocal imaging of a replication- competent, fluorescently tagged HIV-1. J. Virol. 81:12596-12607.
22. Peden K, Emerman M, Montagnier L. 1991. Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI. Virology 185:661-672.
23. Shaner NC, Campbell RE, Steinbach PA, Giepmans BNG, Palmer AE, Tsien RY. 2004. Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat. Biotech. 22:1567-1572.
24. Chang LJ, Urlacher V, Iwakuma T, Cui Y, Zucali J. 1999. Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system. Gene Ther. 6:715-728.
25. Cui Y, Iwakuma T, Chang LJ. 1999. Contributions of viral splice sites and cis-regulatory elements to lentivirus vector function. J. Virol. 73:6171-6176.
26. Iwakuma T, Cui Y, Chang LJ. 1999. Self-inactivating lentiviral vectors with U3 and U5 modifications. Virology 261:120-132.
27. Zolotukhin S, Potter M, Hauswirth W, Guy J, Muzyczka N. 1996. A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J. Virol. 70:4646-4654.
28. Jeeninga RRE, Hoogenkamp M, Armand-Ugon M, De Baar M, Verhoef K, Berkhout B. 2000. Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G. J. Virol. 74:3740-3751.
29. Weiss A, Wiskocil RL, Stobo JD. 1984. The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL 2 production reflects events occurring at a pre-translational level. J. Immunol. 133:123-128.
30. Smith SD, Shatsky M, Cohen PS, Warnke R, Link MP, Glader BE. 1984. Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines. Cancer Res. 44:5657-5660.
31. Dahabieh MS, Ooms M, Malcolm T, Simon V, Sadowski I. 2011. Identification and functional analysis of a second RBF-2 binding site within the HIV-1 promoter. Virology 418:57-66.
32. O'Doherty U, Swiggard W, Malim M. 2000. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J. Virol. 74:10074-10080.
33. Lahm HW, Stein S. 1985. Characterization of recombinant human interleukin- 2 with micromethods. J. Chromatogr. 326:357-361.
34. Marks PA. 2007. Discovery and development of SAHA as an anticancer agent. Oncogene 26:1351-1356.
35. Hübner W, Mcnerney GP, Chen P, Dale BM, Gordon RE, Chuang FYS, Li X, Asmuth DM, Huser T, Chen BK. 2009. Quantitative 3D video microscopy of HIV transfer Across T cell virological synapses. Science 323:1743-1747.
36. Gelderblom HC, Vatakis DN, Burke SA, Lawrie SD, Bristol GC, Levy DN. 2008. Viral complementation allows HIV-1 replication without integration. Retrovirology 5:60. doi:10.1186/1742-4690-5-60.
37. + T lymphocytes: implications for integrase inhibitors. J. Gen. Virol. 86:765-771.
38. Kauder SE, Bosque A, Lindqvist A, Planelles V, Verdin E. 2009. Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog. 5:e1000495. doi:10.1371/journal.ppat.1000495.
39. Folks TM, Clouse KA, Justement J, Rabson A, Duh E, Kehrl JH, Fauci AS. 1989. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc. Natl. Acad. Sci. U. S. A. 86:2365-2368.
40. Folks TM, Justement J, Kinter A, Schnittman S, Orenstein J, Poli G, Fauci AS. 1988. Characterization of a promonocyte clone chronically infected with HIV and inducible by 13-phorbol-12-myristate acetate. J. Immunol. 140:1117-1122.
41. Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, Margolis DM. 2009. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res. Hum. Retroviruses 25: 207-212.
42. Contreras X, Schweneker M, Chen CS, McCune JM, Deeks SG, Martin J, Peterlin BM. 2009. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J. Biol. Chem. 284:6782-6789.
43. Fernandez G, Zeichner SL. 2010. Cell line-dependent variability in HIV activation employing DNMT inhibitors. Virol. J. 7:266.
44. van der Sluis RMRM, Pollakis G, Van Gerven ML, Berkhout B, Jeeninga RE. 2011. Latency profiles of full length HIV-1 molecular clone variants with a subtype specific promoter. Retrovirology 8:73. doi:10.1186/1742-4690-8-73.
45. Hunninghake GW, Monick MM, Liu B, Stinski MF. 1989. The promoterregulatory region of the major immediate-early gene of human cytomegalovirus responds to T-lymphocyte stimulation and contains functional cyclic AMP-response elements. J. Virol. 63:3026-3033.
46. Reeves M, Sinclair J. 2008. Aspects of human cytomegalovirus latency and reactivation. Curr. Top. Microbiol. Immunol. 325:297-313.
47. Sambucetti LC, Cherrington JM, Wilkinson GW, Mocarski ES. 1989. NF-kappa B activation of the cytomegalovirus enhancer is mediated by a viral transactivator and by T cell stimulation. EMBO J. 8:4251-4258.
48. Chan YJ, Chiou CJ, Huang Q, Hayward GS. 1996. Synergistic interactions between overlapping binding sites for the serum response factor and ELK-1 proteins mediate both basal enhancement and phorbol ester responsiveness of primate cytomegalovirus major immediate-early promoters in monocyte and T-lympho. J. Virol. 70:8590-8605.
49. Sinclair J, Sissons P. 1996. Latent and persistent infections of monocytes and macrophages. Intervirology 39:293-301.
50. Sinzger C, Jahn G. 1996. Human cytomegalovirus cell tropism and pathogenesis. Intervirology 39:302-319.
51. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, Boucher G, Boulassel MR, Ghattas G, Brenchley JM, Schacker TW, Hill BJ, Douek DC, Routy JP, Haddad EK, Sekaly RP. 2009. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 15:893-900.
52. Berthoux L, Sebastian S, Muesing MA, Luban J. 2007. The role of lysine 186 in HIV-1 integrase multimerization. Virology 364:227-236.
53. Karn J, Stoltzfus CM. 2012. Transcriptional and posttranscriptional regulation of HIV-1 gene expression. Cold Spring Harb. Perspect. Med. 2:a006916.
54. Siliciano RF, Greene WC. 2011. HIV latency. Cold Spring Harb. Perspect. Med. 1:a007096. doi:10.1101/cshperspect.a007096.